Seattle researchers to engineer kidney tissue chip for predicting drug safety

By Leila Gray
Seattle researchers to engineer kidney tissue chip for predicting drug safety
An example of a tissue chip for drug safety testing. Credit: NCATS

(Medical Xpress) -- Seattle researchers will be part of the new federal initiative to engineer 3-dimensional chips containing living cells and tissues that imitate the structure and function of human organs.  These tissue chips will be used for drug safety testing.

Tissue chips merge techniques from the computer industry with those from bioengineering by combining miniature models of living organ tissues onto a transparent microchip. Ranging in size from a coin to a house key, the chips are lined with living cells and contain features designed to replicate the complex biological function of a specific organ.

The Seattle team will design, implement and test a tissue-engineered human kidney microphysiological system.  Kidneys, which clear the blood of waste products, are among the sensitive organs that can be damaged by certain medications, environmental toxins or an excess of natural substances produced by the body.

The Seattle project, announced July 24, is led by Dr. Jonathan Himmelfarb, University of Washington professor of medicine in the Department of Medicine, Division of Nephrology, and director of the Kidney Research Institute.  The project team consists of physicians, bioengineers, pharmacists, environmental health researchers, and pharmaceutical developers from the UW schools of medicine, public health and pharmacy, and the College of Engineering. The amount  and years of of funding to the UW are yet to be announced, pending Notice of Grant Award. Overall, the national initiative is budgeted at $70 million.

Their project proposal is one of 17 nationwide funded in a recent round of awards from the new National Center for Advancing Translational Sciences of the National Institutes of Health.  This grant program, a collaboration with the Defense Advanced Research Projects Agency and the U.S. Food and Drug Administration, was created to improve methods for predicting whether newly developed drugs will be safe in humans.

The goal is to develop human tissue chips that simulate  the structure and function of human organs, such the lung, heart, liver, and kidneys.  Scientists could then use these tissue chips to test drug candidates and predict their safety before the next step, human drug studies. This approach is expected be more rapid and cost effective than those currently available.

The NIH pointed to studies that show that more than 30 percent of promising medications have failed in human clinical trials because the drugs were found to be toxic, despite pre-clinical studies in animal models. Tissue chips may offer more accurate predictions of the side effects of potential therapeutic agents because they contain human cells.

Ten of the 17 new awards will support studies to design 3-dimensional cellular microsystems that represent different . These bioengineered devices will produce relevant physiological functions and will reflect the complexity and diversity of living organs, including genetic differences, disease complexity and pharmacological responses.  The additional seven National Center for Advancing Translational Sciences awards will explore the potential of stem cells and progenitor cells to form the many cell types that make up the architecture of complex organs. These could be a source of cells to populate tissue chips.

Himmelfarb and his colleagues propose to create a tiny, 3-dimensional lab device containing engineered biological tissues that will perform certain actions of a living human kidney.  The system would evaluate the uptake, breakdown and elimination of potentially toxic substances, and predict the rate for these chemical reactions. The system might also help assess kidney injury from infections disease organisms and from toxins, both those introduced into the body and those produced by the body.

The micro-model of kidney physiology will also feature two parallel structures – small blood vessels and the surface lining of the renal tubules.  This aspect of the device will enable researchers to study the complex interactions between these two structures, which are normally in intimate association inside each of the functional units of the kidney, the nephrons.

In addition to Himmelfarb, the UW project team includes Jeremy Duffield from the Department of Medicine, Division of Nephrology; Ying Zheng from the Department of Bioengineering; Ken Thummel and Joanne Wang from the Department of Pharmaceutics; David Eaton, of the Department of Environmental and Occupational Health and the UW Center for Ecogentics and Environmental Health, and Danny Shen from the Department of Pharmacy.

Nortis Inc., a bioengineering start-up company funded through  the UW’s Center for Commercialization, will also be a partner in the project. Thomas Neumann is president and CEO of Nortis.  Project plans include using the Life Sciences Development Fund-supported Washington Phenotype Biospecimen Resource to obtain specimens for the project.

add to favorites email to friend print save as pdf

Related Stories

Lab-engineered kidney project reaches early milestone

Jun 21, 2012

Regenerative medicine researchers at Wake Forest Baptist Medical Center have reached an early milestone in a long-term project that aims to build replacement kidneys in the lab to help solve the shortage of donor organs.

UW team part of IBM 'cognitive' computing chip project

Aug 19, 2011

(PhysOrg.com) -- University of Wisconsin-Madison researchers are part of the IBM-led team that has unveiled a new generation of experimental computer chips - the first step in a project to create a computer that borrows pri ...

Researchers engineer miniature human livers in the lab

Oct 30, 2010

Researchers at the Institute for Regenerative Medicine at Wake Forest University Baptist Medical Center have reached an early, but important, milestone in the quest to grow replacement livers in the lab. They are the first ...

Stem cells from patients make 'early retina in a dish'

Jun 16, 2011

(PhysOrg.com) -- Soon, some treatments for blinding eye diseases might be developed and tested using retina-like tissues produced from the patient's own skin, thanks to a series of discoveries reported by ...

Recommended for you

Gamers helping in Ebola research

6 hours ago

Months before the recent Ebola outbreak erupted in Western Africa, killing more than a thousand people, scientists at the University of Washington's Institute for Protein Design were looking for a way to stop the deadly virus.

Carcinogenic role of a protein in liver decoded

9 hours ago

The human protein EGFR controls cell growth. It has mutated in case of many cancer cells or exists in excessive numbers. For this reason it serves as a point of attack for target-oriented therapies. A study ...

A new way to diagnose malaria, using magnetic fields

Aug 31, 2014

Over the past several decades, malaria diagnosis has changed very little. After taking a blood sample from a patient, a technician smears the blood across a glass slide, stains it with a special dye, and ...

User comments